{"id":898954,"date":"2025-10-22T12:03:12","date_gmt":"2025-10-22T16:03:12","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/aacr-abstract-first-evidence-that-selective-a2b-receptor-inhibition-lowers-pd-l1-tumor-expression-and-also-directly-suppresses-mesothelioma-tumor-growth\/"},"modified":"2025-10-22T12:03:12","modified_gmt":"2025-10-22T16:03:12","slug":"aacr-abstract-first-evidence-that-selective-a2b-receptor-inhibition-lowers-pd-l1-tumor-expression-and-also-directly-suppresses-mesothelioma-tumor-growth","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/aacr-abstract-first-evidence-that-selective-a2b-receptor-inhibition-lowers-pd-l1-tumor-expression-and-also-directly-suppresses-mesothelioma-tumor-growth\/","title":{"rendered":"AACR Abstract: First Evidence that Selective A2B Receptor Inhibition Lowers PD-L1 Tumor Expression and also Directly Suppresses Mesothelioma Tumor Growth"},"content":{"rendered":"<h2>\nAbstract published today reports reduced adenosine-mediated PD-L1 in a human epithelioid mesothelioma cell line linked to decreased CREB phosphorylation (pCREB). In vivo, TT-4 monotherapy outperformed anti-PD-1 and the combination was superior to either agent alone. Additional data will be presented with the poster on Saturday, October 25<br \/>\n<\/h2>\n<div class=\"mw_release\">\n<p id=\"isPasted\">Dover, DE, Oct.  22, 2025  (GLOBE NEWSWIRE) &#8212; AlphaTON Capital Corp (<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=sERFXXIhHJxIbw4EdCFXvDSujOnRJM3oOvj7ivrXwXSaEZdDdoMJg83ElvMa4vQ0WYR5N83kXX1q1Rj18LU6mHThSzIbdq0TLsgAWiUFdolXiRfT1y7ceUL354PqFlYl\" rel=\"nofollow\" target=\"_blank\">Nasdaq: ATON<\/a>) and its oncology-focused subsidiary Tarus Therapeutics, LLC, operating as Cyncado Therapeutics, announce that the AACR has published online the company\u2019s abstract for presentation at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics.<\/p>\n<p>As described in the abstract, investigators will present\u00a0first\u00a0evidence\u00a0that\u00a0A2B receptor\u00a0inhibition\u00a0reduces the adenosine-mediated increase in PD-L1\u00a0in a\u00a0human epithelioid mesothelioma\u00a0cell line,\u00a0associated with decreased CREB phosphorylation (pCREB). In an\u00a0immunocompetent in vivo mesothelioma model,\u00a0TT-4 monotherapy outperformed anti-PD-1, and\u00a0TT-4 + anti-PD-1\u00a0showed significantly more anti-tumor activity\u00a0than either agent alone; immunohistochemistry showed\u00a0increased T-cell infiltration.<\/p>\n<p>\u201cIn vitro, we see a direct anti-tumor effect in both epithelial and non-epithelial mesothelioma cells, with PD-L1 falling in step with reduced pCREB. In vivo, TT-4 is active as a single agent and adds benefit with anti-PD-1, clear signals that are guiding our clinical strategy,\u201d said Rob Kramer, PhD, Chief Scientific Officer at Cyncado Therapeutics.<\/p>\n<p>\n        <strong>Presentation details<\/strong><br \/>\n        <br \/>\n        <strong>Title<\/strong>: ADORA2B inhibition in Mesothelioma (MMe) cells affects PD-L1 expression and exerts an effective response on AKT signaling and anti-tumor immune response<br \/><strong>Session<\/strong>: Poster Session C<br \/><strong>Location<\/strong>: Boston, Massachusetts<br \/><strong>Date and time<\/strong>: Saturday, October 25, 2025, 12:30\u20134:00 pm EDT<br \/><strong>Presenting group<\/strong>: G.I.Me with collaborators from University of L\u2019Aquila, Istituto Nazionale Tumori IRCCS Fondazione G. Pascale, St. James\u2019s Hospital Dublin, and Cyncado Therapeutics<\/p>\n<p>\n        <strong>About AlphaTON Capital Corp<\/strong><br \/>\n        <br \/>AlphaTON Capital is a specialized digital asset treasury company focused on building and managing a strategic reserve of TON tokens and developing the Telegram ecosystem. The Company implements a comprehensive treasury strategy that combines direct token acquisition, validator operations, and strategic ecosystem investments to generate sustainable returns for shareholders. Through its operations, AlphaTON Capital provides public market investors with institutional-grade exposure to the TON ecosystem and Telegram&#8217;s billion user platform while maintaining the governance standards and reporting transparency of a Nasdaq-listed company.<\/p>\n<p>Led by Chief Executive Officer Brittany Kaiser and Chief Investment Officer, Enzo Villani, the company&#8217;s activities span network validation and staking operations, development of Telegram-based applications, and potential strategic investments in TON-based decentralized finance protocols, gaming platforms, and business applications. AlphaTON Capital Corp is incorporated in the British Virgin Islands and trades on Nasdaq under the ticker symbol\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=9oEiP7duUu_Roa8AEScEkcz6VrSKgPG8JZ-4XKxV3SHfF6F-_ylnXNcYY9HNh78Fj038ja7uqf-X_8d0ywUhLzvTKV6U93Dq5iDqOWnuni6HTHDaHBCIO0DfAK7RTFYu\" rel=\"nofollow\" target=\"_blank\">ATON<\/a>.<\/p>\n<p>AlphaTON Capital, through its legacy business, is also advancing potentially first-in-class therapies that target known checkpoint resistance pathways to potentially achieve durable treatment response and improve quality of life for patients. AlphaTON Capital actively engages in the drug development process and provides strategic counsel to guide development of novel immunotherapy assets and asset combinations.<\/p>\n<p>\n        <strong>About Cyncado Therapeutics<\/strong><br \/>\n        <br \/>Tarus Therapeutics, LLC (operating as Cyncado Therapeutics), a clinical stage, wholly owned subsidiary of AlphaTON Capital Corp, is developing potentially best-in-class small molecule adenosine receptor antagonists targeting A2A and A2B receptors to overcome immune suppression in oncology. The Company&#8217;s lead program, TT-4, is an oral, ultra-selective A2B receptor antagonist with an initial focus on mesothelioma, advancing toward first-patient dosing in Q1 2026. Cyncado is also developing dual-antagonist strategies designed to achieve comprehensive blockade of adenosine-mediated immune evasion, potentially unlocking synergistic anti-tumor effects and durable patient responses.<\/p>\n<p>\n        <strong>Forward-Looking Statements<\/strong><br \/>\n        <br \/>This press release contains forward-looking statements within the meaning of applicable securities laws. All statements other than statements of historical fact, including statements regarding the Company&#8217;s business strategy, plans and objectives, future operations, clinical development timelines, TON ecosystem growth, therapeutic development outcomes, regulatory approvals, financing activities, and statements preceded by, followed by, or including words such as &#8220;believe,&#8221; &#8220;expects,&#8221; &#8220;anticipates,&#8221; &#8220;intends,&#8221; &#8220;estimates,&#8221; &#8220;will,&#8221; &#8220;may,&#8221; &#8220;plans,&#8221; &#8220;potential,&#8221; &#8220;targets,&#8221; or similar expressions, are forward-looking statements.<\/p>\n<p>These forward-looking statements are subject to substantial risks and uncertainties, including but not limited to: uncertainty regarding clinical trial outcomes and regulatory approvals; uncertainty of the Company&#8217;s investment in TON and digital assets; regulatory and legal risks associated with digital assets; risks related to Telegram&#8217;s platform and the TON ecosystem; market volatility; competitive risks in both digital assets and therapeutics development; and other factors described in &#8220;Item 3 \u2013 Key Information-Risk Factors&#8221; in the Company&#8217;s Annual Report on Form 20-F for the year ended March 31, 2025, and subsequent reports filed with the Securities and Exchange Commission.<\/p>\n<p>Although the Company believes the expectations reflected in these forward-looking statements are reasonable, actual results may differ materially. The Company undertakes no obligation to update publicly or revise any forward-looking statements, except as required by law.<\/p>\n<p>\n        <strong>Contact Information<\/strong>\n      <\/p>\n<p>\n        <strong>Investor Relations<\/strong><br \/>\n        <br \/>\u00a0AlphaTON Capital Corp<br \/>\u00a0AlphaTON@icrinc.com<br \/>\u00a0(203) 682-8200<\/p>\n<p>\n        <strong>Media Inquiries<\/strong><br \/>\n        <br \/>\u00a0Richard Laermer<br \/>\u00a0RLM PR<br \/>\u00a0AlphaTON@rlmpr.com<br \/>\u00a0(212) 741-5106 X 216<\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU0OTg3MCM3MjA4MzUyIzUwMDE1MDk1Mw==\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/NWU4ZjcwYmQtMjgxMS00MmVmLWE0YmItYWI2MDJkZjQyZjdkLTUwMDE1MDk1My0yMDI1LTEwLTIyLWVu\/tiny\/AlphaTON-Capital.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\">\n<pre>Richard Laermer\r\nAlphaTON (at) rlmpr.com<\/pre>\n<\/p><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Abstract published today reports reduced adenosine-mediated PD-L1 in a human epithelioid mesothelioma cell line linked to decreased CREB phosphorylation (pCREB). In vivo, TT-4 monotherapy outperformed anti-PD-1 and the combination was superior to either agent alone. Additional data will be presented with the poster on Saturday, October 25 Dover, DE, Oct. 22, 2025 (GLOBE NEWSWIRE) &#8212; AlphaTON Capital Corp (Nasdaq: ATON) and its oncology-focused subsidiary Tarus Therapeutics, LLC, operating as Cyncado Therapeutics, announce that the AACR has published online the company\u2019s abstract for presentation at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics. As described in the abstract, investigators will present\u00a0first\u00a0evidence\u00a0that\u00a0A2B receptor\u00a0inhibition\u00a0reduces the adenosine-mediated increase in PD-L1\u00a0in a\u00a0human epithelioid mesothelioma\u00a0cell line,\u00a0associated with decreased CREB phosphorylation (pCREB). In an\u00a0immunocompetent in &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/aacr-abstract-first-evidence-that-selective-a2b-receptor-inhibition-lowers-pd-l1-tumor-expression-and-also-directly-suppresses-mesothelioma-tumor-growth\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;AACR Abstract: First Evidence that Selective A2B Receptor Inhibition Lowers PD-L1 Tumor Expression and also Directly Suppresses Mesothelioma Tumor Growth&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-898954","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>AACR Abstract: First Evidence that Selective A2B Receptor Inhibition Lowers PD-L1 Tumor Expression and also Directly Suppresses Mesothelioma Tumor Growth - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/aacr-abstract-first-evidence-that-selective-a2b-receptor-inhibition-lowers-pd-l1-tumor-expression-and-also-directly-suppresses-mesothelioma-tumor-growth\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"AACR Abstract: First Evidence that Selective A2B Receptor Inhibition Lowers PD-L1 Tumor Expression and also Directly Suppresses Mesothelioma Tumor Growth - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Abstract published today reports reduced adenosine-mediated PD-L1 in a human epithelioid mesothelioma cell line linked to decreased CREB phosphorylation (pCREB). In vivo, TT-4 monotherapy outperformed anti-PD-1 and the combination was superior to either agent alone. Additional data will be presented with the poster on Saturday, October 25 Dover, DE, Oct. 22, 2025 (GLOBE NEWSWIRE) &#8212; AlphaTON Capital Corp (Nasdaq: ATON) and its oncology-focused subsidiary Tarus Therapeutics, LLC, operating as Cyncado Therapeutics, announce that the AACR has published online the company\u2019s abstract for presentation at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics. As described in the abstract, investigators will present\u00a0first\u00a0evidence\u00a0that\u00a0A2B receptor\u00a0inhibition\u00a0reduces the adenosine-mediated increase in PD-L1\u00a0in a\u00a0human epithelioid mesothelioma\u00a0cell line,\u00a0associated with decreased CREB phosphorylation (pCREB). In an\u00a0immunocompetent in &hellip; Continue reading &quot;AACR Abstract: First Evidence that Selective A2B Receptor Inhibition Lowers PD-L1 Tumor Expression and also Directly Suppresses Mesothelioma Tumor Growth&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/aacr-abstract-first-evidence-that-selective-a2b-receptor-inhibition-lowers-pd-l1-tumor-expression-and-also-directly-suppresses-mesothelioma-tumor-growth\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-10-22T16:03:12+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU0OTg3MCM3MjA4MzUyIzUwMDE1MDk1Mw==\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aacr-abstract-first-evidence-that-selective-a2b-receptor-inhibition-lowers-pd-l1-tumor-expression-and-also-directly-suppresses-mesothelioma-tumor-growth\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aacr-abstract-first-evidence-that-selective-a2b-receptor-inhibition-lowers-pd-l1-tumor-expression-and-also-directly-suppresses-mesothelioma-tumor-growth\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"AACR Abstract: First Evidence that Selective A2B Receptor Inhibition Lowers PD-L1 Tumor Expression and also Directly Suppresses Mesothelioma Tumor Growth\",\"datePublished\":\"2025-10-22T16:03:12+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aacr-abstract-first-evidence-that-selective-a2b-receptor-inhibition-lowers-pd-l1-tumor-expression-and-also-directly-suppresses-mesothelioma-tumor-growth\\\/\"},\"wordCount\":812,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aacr-abstract-first-evidence-that-selective-a2b-receptor-inhibition-lowers-pd-l1-tumor-expression-and-also-directly-suppresses-mesothelioma-tumor-growth\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTU0OTg3MCM3MjA4MzUyIzUwMDE1MDk1Mw==\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aacr-abstract-first-evidence-that-selective-a2b-receptor-inhibition-lowers-pd-l1-tumor-expression-and-also-directly-suppresses-mesothelioma-tumor-growth\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aacr-abstract-first-evidence-that-selective-a2b-receptor-inhibition-lowers-pd-l1-tumor-expression-and-also-directly-suppresses-mesothelioma-tumor-growth\\\/\",\"name\":\"AACR Abstract: First Evidence that Selective A2B Receptor Inhibition Lowers PD-L1 Tumor Expression and also Directly Suppresses Mesothelioma Tumor Growth - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aacr-abstract-first-evidence-that-selective-a2b-receptor-inhibition-lowers-pd-l1-tumor-expression-and-also-directly-suppresses-mesothelioma-tumor-growth\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aacr-abstract-first-evidence-that-selective-a2b-receptor-inhibition-lowers-pd-l1-tumor-expression-and-also-directly-suppresses-mesothelioma-tumor-growth\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTU0OTg3MCM3MjA4MzUyIzUwMDE1MDk1Mw==\",\"datePublished\":\"2025-10-22T16:03:12+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aacr-abstract-first-evidence-that-selective-a2b-receptor-inhibition-lowers-pd-l1-tumor-expression-and-also-directly-suppresses-mesothelioma-tumor-growth\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aacr-abstract-first-evidence-that-selective-a2b-receptor-inhibition-lowers-pd-l1-tumor-expression-and-also-directly-suppresses-mesothelioma-tumor-growth\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aacr-abstract-first-evidence-that-selective-a2b-receptor-inhibition-lowers-pd-l1-tumor-expression-and-also-directly-suppresses-mesothelioma-tumor-growth\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTU0OTg3MCM3MjA4MzUyIzUwMDE1MDk1Mw==\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTU0OTg3MCM3MjA4MzUyIzUwMDE1MDk1Mw==\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aacr-abstract-first-evidence-that-selective-a2b-receptor-inhibition-lowers-pd-l1-tumor-expression-and-also-directly-suppresses-mesothelioma-tumor-growth\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"AACR Abstract: First Evidence that Selective A2B Receptor Inhibition Lowers PD-L1 Tumor Expression and also Directly Suppresses Mesothelioma Tumor Growth\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"AACR Abstract: First Evidence that Selective A2B Receptor Inhibition Lowers PD-L1 Tumor Expression and also Directly Suppresses Mesothelioma Tumor Growth - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/aacr-abstract-first-evidence-that-selective-a2b-receptor-inhibition-lowers-pd-l1-tumor-expression-and-also-directly-suppresses-mesothelioma-tumor-growth\/","og_locale":"en_US","og_type":"article","og_title":"AACR Abstract: First Evidence that Selective A2B Receptor Inhibition Lowers PD-L1 Tumor Expression and also Directly Suppresses Mesothelioma Tumor Growth - Market Newsdesk","og_description":"Abstract published today reports reduced adenosine-mediated PD-L1 in a human epithelioid mesothelioma cell line linked to decreased CREB phosphorylation (pCREB). In vivo, TT-4 monotherapy outperformed anti-PD-1 and the combination was superior to either agent alone. Additional data will be presented with the poster on Saturday, October 25 Dover, DE, Oct. 22, 2025 (GLOBE NEWSWIRE) &#8212; AlphaTON Capital Corp (Nasdaq: ATON) and its oncology-focused subsidiary Tarus Therapeutics, LLC, operating as Cyncado Therapeutics, announce that the AACR has published online the company\u2019s abstract for presentation at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics. As described in the abstract, investigators will present\u00a0first\u00a0evidence\u00a0that\u00a0A2B receptor\u00a0inhibition\u00a0reduces the adenosine-mediated increase in PD-L1\u00a0in a\u00a0human epithelioid mesothelioma\u00a0cell line,\u00a0associated with decreased CREB phosphorylation (pCREB). In an\u00a0immunocompetent in &hellip; Continue reading \"AACR Abstract: First Evidence that Selective A2B Receptor Inhibition Lowers PD-L1 Tumor Expression and also Directly Suppresses Mesothelioma Tumor Growth\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/aacr-abstract-first-evidence-that-selective-a2b-receptor-inhibition-lowers-pd-l1-tumor-expression-and-also-directly-suppresses-mesothelioma-tumor-growth\/","og_site_name":"Market Newsdesk","article_published_time":"2025-10-22T16:03:12+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU0OTg3MCM3MjA4MzUyIzUwMDE1MDk1Mw==","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aacr-abstract-first-evidence-that-selective-a2b-receptor-inhibition-lowers-pd-l1-tumor-expression-and-also-directly-suppresses-mesothelioma-tumor-growth\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aacr-abstract-first-evidence-that-selective-a2b-receptor-inhibition-lowers-pd-l1-tumor-expression-and-also-directly-suppresses-mesothelioma-tumor-growth\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"AACR Abstract: First Evidence that Selective A2B Receptor Inhibition Lowers PD-L1 Tumor Expression and also Directly Suppresses Mesothelioma Tumor Growth","datePublished":"2025-10-22T16:03:12+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aacr-abstract-first-evidence-that-selective-a2b-receptor-inhibition-lowers-pd-l1-tumor-expression-and-also-directly-suppresses-mesothelioma-tumor-growth\/"},"wordCount":812,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aacr-abstract-first-evidence-that-selective-a2b-receptor-inhibition-lowers-pd-l1-tumor-expression-and-also-directly-suppresses-mesothelioma-tumor-growth\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU0OTg3MCM3MjA4MzUyIzUwMDE1MDk1Mw==","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aacr-abstract-first-evidence-that-selective-a2b-receptor-inhibition-lowers-pd-l1-tumor-expression-and-also-directly-suppresses-mesothelioma-tumor-growth\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/aacr-abstract-first-evidence-that-selective-a2b-receptor-inhibition-lowers-pd-l1-tumor-expression-and-also-directly-suppresses-mesothelioma-tumor-growth\/","name":"AACR Abstract: First Evidence that Selective A2B Receptor Inhibition Lowers PD-L1 Tumor Expression and also Directly Suppresses Mesothelioma Tumor Growth - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aacr-abstract-first-evidence-that-selective-a2b-receptor-inhibition-lowers-pd-l1-tumor-expression-and-also-directly-suppresses-mesothelioma-tumor-growth\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aacr-abstract-first-evidence-that-selective-a2b-receptor-inhibition-lowers-pd-l1-tumor-expression-and-also-directly-suppresses-mesothelioma-tumor-growth\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU0OTg3MCM3MjA4MzUyIzUwMDE1MDk1Mw==","datePublished":"2025-10-22T16:03:12+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aacr-abstract-first-evidence-that-selective-a2b-receptor-inhibition-lowers-pd-l1-tumor-expression-and-also-directly-suppresses-mesothelioma-tumor-growth\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/aacr-abstract-first-evidence-that-selective-a2b-receptor-inhibition-lowers-pd-l1-tumor-expression-and-also-directly-suppresses-mesothelioma-tumor-growth\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aacr-abstract-first-evidence-that-selective-a2b-receptor-inhibition-lowers-pd-l1-tumor-expression-and-also-directly-suppresses-mesothelioma-tumor-growth\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU0OTg3MCM3MjA4MzUyIzUwMDE1MDk1Mw==","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU0OTg3MCM3MjA4MzUyIzUwMDE1MDk1Mw=="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aacr-abstract-first-evidence-that-selective-a2b-receptor-inhibition-lowers-pd-l1-tumor-expression-and-also-directly-suppresses-mesothelioma-tumor-growth\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"AACR Abstract: First Evidence that Selective A2B Receptor Inhibition Lowers PD-L1 Tumor Expression and also Directly Suppresses Mesothelioma Tumor Growth"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/898954","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=898954"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/898954\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=898954"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=898954"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=898954"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}